Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-ranging Study of Abiprubart in Sjögren’s Disease
2024-512986-15-00Phase 2Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome comparing Abiprubart (KPL-404) with Placebo (2 arms). Primary endpoint: Change from baseline in ESSDAI at Week 24. Started Dec 2024; status: completed.
02
Drugs
Abiprubart
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2024-512986-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512986-15-00.